Good call on the CEO's part.. FDA clearly was comfortable with discussing with him their feelings that Mild & Moderate patients didn't have a dire need for Leronlimab, and there were already approved treatments. Saved the company from a PR that Feuerstain and the rest of his turds would have had a field day with, and really underscores the communication channels CytoDyn has with the FDA.. if they don't like you, they just ignore you.